How Urolithin A Improves Mitochondrial Function

Urolithin A improves mitochondrial function primarily by triggering mitophagy, the process by which cells identify and recycle damaged mitochondria. Think of it as a quality-control signal: instead of letting worn-out mitochondria accumulate and drag down cellular energy production, urolithin A flags them for disposal and, in parallel, stimulates the creation of fresh replacements. The compound is not a nutrient you eat directly from food but rather a metabolite your gut bacteria produce when you consume certain plant polyphenols, which adds an unusual layer of individual variability to who actually benefits.

Where Urolithin A Comes From

You do not absorb urolithin A from pomegranates, walnuts, or berries themselves. Those foods supply ellagitannins and ellagic acid, which are large polyphenol molecules. Once they reach the colon, specific gut bacteria break them down in a multi-step process that eventually yields urolithin A. The conversion is not universal. People fall into distinct “urolithin metabotypes” based on what their microbiome can do: metabotype A individuals produce mainly urolithin A, metabotype B individuals produce urolithin B and isourolithin A alongside urolithin A, and metabotype 0 individuals produce little to no urolithins at all.¹

The bacteria doing the heavy lifting have been narrowing down in recent research. Species in the genus Enterocloster, particularly E. asparagiformis and E. bolteae, carry a newly identified gene cluster called the ucd operon that encodes the dehydroxylase enzyme responsible for a key conversion step.² Bifidobacterium species, including B. longum and B. adolescentis, have also been linked to urolithin A production in fermentation experiments.³ The involvement of multiple bacterial taxa at different steps helps explain why the capacity to produce urolithin A varies so much between people.

The metabotype distinction matters for health beyond urolithin A itself. People classified as metabotype B tend to carry higher levels of bacteria from the Coriobacteriaceae family, which correlates with higher total cholesterol, higher LDL cholesterol, and higher body mass index compared to metabotype A individuals.⁴ Metabotype A, by contrast, has been characterized as the more “protective” profile. So your gut microbiome’s ability to produce urolithin A may itself be a marker of broader metabolic health, not just a quirk of digestion.

The Core Mechanism: Clearing Out Damaged Mitochondria

Mitochondria generate most of your cells’ energy, but they take a beating in the process and accumulate damage over time. A healthy cell constantly monitors mitochondrial quality and removes units that have become inefficient or are leaking harmful byproducts. This targeted cleanup is mitophagy, and it is the central way urolithin A improves mitochondrial function.

The best-studied pathway works through two proteins called PINK1 and Parkin. When a mitochondrion loses its membrane potential (a sign of damage), PINK1 stabilizes on its outer surface and recruits Parkin. Parkin then tags the mitochondrion’s surface proteins with ubiquitin, which acts like a “discard” label. Adaptor proteins recognize that label and guide the damaged mitochondrion into an autophagosome, a membrane-bound sac that fuses with a lysosome to break down the contents.⁵ Urolithin A activates this pathway, but it can also work through PINK1/Parkin-independent routes by engaging proteins like BNIP3 and NIX that directly recruit the cleanup machinery.⁶

The practical result is that a cell exposed to urolithin A ends up with a smaller but healthier population of mitochondria. The damaged ones are gone, and the remaining ones work more efficiently. In a mouse model of motor neuron disease exposed to copper toxicity, urolithin A administration restored the expression of PINK1 and Parkin (both of which had been suppressed), reversed mitochondrial dysfunction, reduced neuroinflammation, and improved muscle function.⁷

Beyond Cleanup: Building New Mitochondria

Removing damaged mitochondria is only half the story. Urolithin A also appears to stimulate the production of new ones, a process called mitochondrial biogenesis. In muscle cells grown in the lab, urolithin A treatment boosted the activation of an energy-sensing enzyme called AMPK by roughly 40% compared to untreated cells, and increased levels of PGC-1α, a protein widely considered the master regulator of mitochondrial biogenesis.⁸ Those same cells showed higher maximal respiratory capacity, meaning they could produce more energy when pushed to their limit.

This dual action, removing the bad and building the good, distinguishes urolithin A from interventions that only target one side. The activated PGC-1α also triggers the release of factors that support new blood vessel growth in muscle tissue, which could further improve oxygen delivery and energy production.⁹ A recent immune-cell study found that urolithin A increased both the maximal oxygen consumption rate and the spare respiratory capacity of human microglial cells, suggesting the biogenesis effect is not limited to muscle.¹⁰

What Human Trials Show About Muscle and Exercise

Animal and cell studies are encouraging, but urolithin A’s track record in human clinical trials is more mixed, and the nuances are worth understanding. In a randomized trial of older adults given 1,000 mg of urolithin A daily for four months, the supplement significantly improved muscle endurance in two specific muscles, with participants able to perform more contractions before fatigue at the two-month mark compared to placebo. Plasma levels of ceramides and C-reactive protein (an inflammation marker) also dropped.¹¹ However, the same trial found no significant difference in maximal ATP production rate or six-minute walk distance between the urolithin A and placebo groups. So endurance against fatigue improved, but peak energy output and overall walking performance did not clearly change.

In younger, resistance-trained male athletes, an eight-week trial of urolithin A supplementation found significant improvements in maximal voluntary isometric contraction and repetitions to fatigue compared to placebo. Strength measures like one-rep-max bench press and squat also trended higher in the urolithin A group, but those differences did not reach statistical significance. The supplement did significantly lower C-reactive protein.¹²

The emerging pattern is that urolithin A seems more reliable at improving muscle endurance and reducing inflammation markers than at boosting raw strength or peak power output. That makes sense mechanistically: clearing damaged mitochondria and building new ones would primarily improve how long a muscle can sustain effort before fatigue, not necessarily how much force it can generate in a single burst.

At the gene-expression level, a transcriptomic study in human muscle cells found that urolithin A predominantly affected oxidative phosphorylation and mitochondrial dysfunction pathways, consistent with the mitophagy mechanism, while also influencing genes involved in muscle cell fusion and signaling.¹³

Effects on the Brain

Mitochondrial dysfunction is increasingly recognized as a contributor to neurodegenerative diseases, and urolithin A’s mitophagy-boosting ability has drawn attention in Alzheimer’s research. In Alzheimer’s mouse models, long-term urolithin A treatment improved learning, memory, and olfactory function while also restoring lysosomal function, which is the downstream waste-disposal step that mitophagy depends on.¹⁴

A separate mouse study found that urolithin A reduced amyloid-beta plaques, decreased the clustering of reactive immune cells around plaques, prevented neuron death, and enhanced the birth of new neurons in the brain. The anti-inflammatory mechanism involved activating AMPK while suppressing inflammatory signaling through NF-κB.¹⁵ Urolithin A has also shown neuroprotective effects by inhibiting the production of inflammatory cytokines triggered by amyloid-beta.¹⁶

There is an important connection between the mitophagy mechanism and the anti-inflammatory effects: in microglia (the brain’s resident immune cells), knocking down the PINK1 gene eliminated urolithin A’s ability to reduce the pro-inflammatory molecule TNF-alpha and increase the anti-inflammatory molecule IL-10.⁵ In other words, urolithin A’s anti-inflammatory action in the brain appears to work through mitophagy itself, not as a separate effect. Damaged mitochondria leak signals that ramp up inflammation; clearing them out quiets the inflammatory response. None of this has yet been tested in human brain-health trials, so the Alzheimer’s findings remain preclinical.

Cardiovascular and Immune Benefits

The reach of improved mitochondrial function extends well beyond muscle and brain. In preclinical models, urolithin A reduced both systolic and diastolic cardiac dysfunction in aging and heart-failure models, with the improvements linked to recovery of mitochondrial structural defects. In healthy older adults who took urolithin A for four months, plasma ceramides that are clinically validated as cardiovascular risk predictors dropped significantly.¹⁷ Higher plasma urolithin A levels have also been positively associated with improved endothelial function, particularly in people eating a Mediterranean-style diet.⁵

On the immune side, a randomized placebo-controlled trial in middle-aged and older adults found that urolithin A supplementation affected mitochondria within CD8+ T cells (the immune cells responsible for fighting viruses and cancer) and appeared to promote mitochondrial biogenesis in those cells via PGC-1α.¹⁸ At the systemic level, plasma IL-2 decreased without triggering increases in pro-inflammatory cytokines. When immune cells from participants were stimulated in the lab, CD8+ T cells from the urolithin A group produced more TNF (indicating a stronger antiviral-type response) without shifting toward an allergic-type response, and monocytes showed improved ability to engulf bacteria. These findings suggest urolithin A may help counteract the well-documented decline in immune function that comes with aging, though larger and longer trials are still needed.

The Lifespan Evidence From Model Organisms

The foundational paper that put urolithin A on the map, published in Nature Medicine in 2016, demonstrated that the compound extended lifespan in the roundworm C. elegans by about 45%, while its precursor ellagic acid had no effect at all.⁵ The worms did not just live longer; they maintained normal activity levels, including movement and feeding, while their untreated counterparts declined. The treated worms also preserved their mitochondrial respiratory capacity with age, rather than losing it as normally happens.¹⁹

Anti-aging effects were later confirmed in worm models of Werner syndrome, a premature aging condition, and in mouse models of Duchenne muscular dystrophy, where urolithin A significantly improved survival. Translating lifespan extension from worms to humans is always a stretch, of course. Worms have roughly 1,000 cells and live for weeks. But the consistency of the mitophagy mechanism across species, from worms to mice to human cell cultures, lends credibility to the idea that the same basic process is relevant in human aging.

Why You Might Not Make Enough From Food Alone

Even if you eat plenty of pomegranates, walnuts, and berries, your actual urolithin A levels depend almost entirely on your gut microbiome composition. A study of 100 healthy adults found that direct supplementation with 500 mg of urolithin A produced plasma levels about six times higher than drinking a glass of pomegranate juice, and the variability between individuals was dramatically smaller with the supplement.²⁰ To match a 500 mg supplement dose through diet alone, an average person would need to drink roughly six glasses (about 1.5 liters) of pomegranate juice that contained the necessary precursors, and even then, the actual conversion would vary wildly depending on individual microbiome composition.

This is the fundamental challenge with trying to get urolithin A from food. It is not like vitamin C, where the amount in an orange is the amount you absorb. Your body has to manufacture urolithin A from raw materials, and many people’s gut bacteria simply cannot do that efficiently. Direct supplementation sidesteps the microbiome bottleneck entirely.

What Happens After You Absorb It

Once urolithin A enters circulation, the body rapidly converts it into conjugated forms, mainly urolithin A glucuronide and urolithin A sulfate. In mouse studies, free urolithin A was only detectable in urine at the three-hour mark, after which conjugated metabolites dominated.²¹ This rapid metabolism creates an interesting puzzle for researchers. Pharmacokinetic modeling has suggested that the plasma concentrations achievable through oral supplementation are far below the concentrations used in many cell-culture studies showing dramatic effects.²²

That gap between test-tube concentrations and real-world blood levels is worth keeping in mind when evaluating cell-based studies. The fact that clinical trials do show benefits despite low plasma concentrations suggests that either the conjugated metabolites retain some biological activity, or that urolithin A accumulates in specific tissues at higher concentrations than what shows up in blood, or that even low levels are enough to nudge mitophagy in the right direction. Researchers have not fully sorted this out yet.

Safety Profile

Urolithin A has a reassuring safety record so far. Comprehensive toxicology testing found no genotoxicity across a battery of assays, and 90-day feeding studies in animals showed no adverse effects on clinical parameters, blood chemistry, or organ health at doses far exceeding what any supplement provides. The no-observed-adverse-effect level was the highest dose tested, equivalent to over 3,400 mg per kilogram of body weight per day.²³ For context, a 70 kg person taking a 1,000 mg supplement is consuming roughly 14 mg per kilogram, orders of magnitude below that safety threshold. Human trials to date have reported no significant adverse events at the doses studied.

One nuance worth flagging: urolithin A has been shown to elevate reactive oxygen species in some cell types, such as microglial cells, even while improving their respiratory capacity.¹⁰ Whether that translates to any concern at supplemental doses in humans is unknown, and it may simply reflect the normal increase in mitochondrial activity. Still, it is a reminder that “natural metabolite” does not automatically mean “no biological tradeoffs.”

Figuring Out Your Producer Status

Given that the ability to produce urolithin A varies so much between people, knowing your own producer status has practical value. The most straightforward approach used in research involves drinking pomegranate juice and then measuring urolithin A metabolites in blood or urine afterward. In the study of 100 healthy adults, this simple challenge test reliably separated producers from non-producers, and researchers validated that dried blood spot measurements correlated almost perfectly (Pearson coefficient of 0.97) with standard plasma measurements, raising the possibility of at-home testing in the future.²⁰

Some direct-to-consumer microbiome testing companies have begun including urolithin metabotype information in their reports, though the accuracy and actionability of those results remain unvalidated. The more pragmatic takeaway for most people is simpler: if you are interested in urolithin A’s mitochondrial benefits and you are not eating a diet naturally rich in ellagitannin-containing foods (or even if you are, but you do not know whether your gut can do the conversion), direct supplementation is the more reliable path to consistent levels. The science of who produces what, and why, is still catching up to the supplements already on the market.